Last reviewed · How we verify
Rocbrutinib tablets
At a glance
| Generic name | Rocbrutinib tablets |
|---|---|
| Sponsor | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocbrutinib tablets CI brief — competitive landscape report
- Rocbrutinib tablets updates RSS · CI watch RSS
- Guangzhou Lupeng Pharmaceutical Company LTD. portfolio CI